

BEIGENE'S INTERNAL PIPELINE

THREE LATE-STAGE, AND EIGHT EARLY-STAGE CLINICAL ASSETS



ASSETS	PROGRAMS	DOSE ESC.		DOSE EXPANSION		PIVOTAL		FILED	MARKET	
		PH1a		PH1b	PH2*	PH2**	PH3			
zanubrutinib (BTK)	monotherapy	R/R MCL (approved in multiple geographies)								
		WM (approved by FDA in the U.S. 09.01.21)								
		R/R MZL (accelerated approval by FDA in the U.S. 09.15.21)								
		WM† (filings accepted in multiple geographies; received positive CHMP opinion in the EU)								
		R/R MCL, R/R CLL/SLL (conditionally approved by NMPA in China 06.03.20)								
	R/R WM (conditionally approved by NMPA in China 06.18.21)									
	combination	IL CLL/SLL, R/R CLL/SLL								
		Lupus nephritis								
		Previously treated CLL/SLL (ibrutinib acalabrutinib intolerant)								
		+rituximab IL MCL								
+obinutuzumab R/R FL										
tislelizumab (PD-1)	monotherapy	+lenalidomide +/- ritux. R/R DLBCL								
		R/R cHL (approved 12.26.19), 2L+ UC (approved 04.10.20), 2L/3L HCC (approved 06.23.2021)								
		2L/3L NSCLC, MSI-H or dMMR solid tumors, 2L ESCC								
	+ chemo	2L ESCC (filing accepted by the FDA in the U.S.)								
		IL HCC								
		R/R NK/T-cell lymphoma								
		IL Sq. NSCLC (approved 01.13.21), IL non-Sq. NSCLC (approved 06.23.21)								
		IL NPC (filings accepted in China 08.22.21)								
		IL SCLC, Stage III/IV NSCLC, Localized ESCC								
		IL GC, IL ESCC								
+ pamiparib (PARP) + zanubrutinib (BTK)	Solid tumors									
	B-cell malignancies									
	3L pBRCA+ OC (approved 05.07.21)									
	2L platinum-sensitive OC maintenance									
	IL platinum-sensitive GC maintenance									
pamiparib (PARP)	monotherapy	HER2- BRCA mutated breast cancer								
		Solid tumors								
	+ TMZ (chemo) + RT/TMZ (RT/chemo)	Glioblastoma								
		Solid tumors								
		IL NSCLC								
ociperlimab (BGB-A1217, TIGIT)	+ tislelizumab	R/M Cervical Cancer, R/M ESCC^								
		Solid tumors								
	+ tislelizumab + cCRT	IL SCLC								
		Stage III unresectable NSCLC								
		IL NSCLC								
+ tislelizumab + chemo + tislelizumab + BAT I706	IL HCC									
	B-Raf or K-RAS/N-RAS-mutated solid tumors									
lifirafenib (RAF Dimer) BGB-A425 (TIM-3) BGB-A333 (PD-L1) BGB-A445 (OX40) BGB-11417 (BCL-2) BGB-10188 (PI3-Kδ) BGB-15025 (HPK1)	monotherapy & + tislelizumab	Solid tumors								
		Solid tumors								
	monotherapy & + tislelizumab	Solid tumors								
		Solid tumors								
	monotherapy & + zanubrutinib	B-cell malignancies								
		monotherapy & + tislelizumab; + zanubrutinib	B-cell malignancies; Solid tumors							
monotherapy & + tislelizumab	Advanced solid tumors									

*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. † R/R or not suitable for chemo-immunotherapy; ^R/M: Recurrent / Meta static

BEIGENE'S COLLABORATIVE PIPELINE

COMPOUND	(TARGET) / PROGRAM	DOSE ESC.	DOSE EXPANSION		PIVOTAL		COMMERCIAL RIGHTS	PARTNER	
		PH1a	PH1b	PH2*	PH2**	PH3			
sotorasib	(KRAS G12C)	Solid Tumors, NSCLC, CRC							
ravurutamab ^{AA}	(BCMA)	MM							
AMG 176	(Mcl-1, SM (i.v.))	Hematologic malignancies							
AMG 330 ^A	(CD33)	Myeloid malignancies							
AMG 673 ^{AA}	(CD33)	AML							
AMG 427 ^{AA}	(FLT3)	AML							
tarlatamab ^{AA}	(DLL3)	SCLC							
acapatamab ^{AA}	(PSMA)	Prostate cancer							
AMG 509 ^A	(STEAP1 X mAb)	Prostate cancer						China	Amgen
AMG 199 ^{AA}	(MUC17)	GC/GEJC							
AMG 910 ^{AA}	(Anti-CLDN18.2)	GC/GEJC							
AMG 650	(oral small molecule)	Solid tumors							
AMG 506	(FAP x 4-1BB, DARPIn®)	Solid tumors							
AMG 994		Solid tumors							
AMG 397	(MCL-1)	Myeloid malignancies							
AMG 256	(Anti-PD-1 x IL21 mutein)	Solid tumors							
sitravatinib [†]	(multi-kinase inhibitor) + tislelizumab	NSCLC, RCC, OC, MEL						Asia ex-Japan, AU, NZ	Mirati
	Mono, + tislelizumab	HCC, GC/GEJC							
zanidatamab ^{††}	(HER2, bispecific antibody)	Breast cancer, GEA						Asia ex-Japan, AU, NZ	Zymeworks
		Biliary tract cancers							
ZW49	(HER2, bispecific ADC)	HER2-expressing cancers						Asia ex-Japan, AU, NZ	Zymeworks
BGB-3245 ¹	(B-RAF)	Solid tumors						Asia ex-Japan	SpringWorks ¹
BA3017	(CTLA4) Mono, + tislelizumab	Tech transfer in progress						Global	BioAtla
SEA-CD70	(anti-CD70)	MDS, AML						Asia ex-Japan, AU, NZ	Seagen
DKN-01	(DKK1) + tislelizumab ± chemo	GC/GEJC						Asia ex-Japan, AU, NZ	Leap Therapeutics
ABI-H0731	(HBV core inhibitor)	Chronic Hepatitis B Virus							
ABI-H2158	(HBV core inhibitor)	Chronic Hepatitis B Virus						China	Assembly Bio
ABI-H3733	(HBV core inhibitor)	Chronic Hepatitis B Virus							

* Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated or conditional approvals. ^A BITE, ^{AA} HLE BITE, [†] Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non-Sq NSCLC. ^{††} ZW25, AML: acute myeloid leukemia, HLE BITE: Half-life extended Bi-specific T-cell engagers, GC/GEJ: gastric cancer/gastroesophageal junction, HCC: hepatocellular carcinoma, IND: Investigational New Drug, MEL: melanoma, MM: multiple myeloma, NHL: non-Hodgkin's lymphoma, NSCLC: non-small cell lung cancer, OC: ovarian cancer, RCC: renal cell carcinoma, SM: small molecule; 1. By MapKure, a JV with SpringWorks